SODIUM POLYPHOSPHATE-TIN KIT

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SODIUM POLYPHOSPHATE-TIN KIT (SODIUM POLYPHOSPHATE-TIN KIT).

How it works

Sodium polyphosphate-tin kit is used for radiolabeling with technetium-99m to form Tc-99m tin colloid, which is taken up by the reticuloendothelial system (liver, spleen, bone marrow) via phagocytosis. The mechanism of action for imaging involves targeting the mononuclear phagocytic system.

What the body does with it

Metabolism	Not metabolized; the colloid is sequestered by phagocytic cells in the liver, spleen, and bone marrow, and the radionuclide decays physically.
Excretion	Renal elimination of technetium-99m pertechnetate and polyphosphate. Approximately 30% excreted in urine within 24 hours; remainder cleared via bone uptake and slow release. Fecal excretion negligible.
Half-life	Terminal half-life of technetium-99m pertechnetate: 6 hours (physical decay). Biological half-life of polyphosphate variable; bone-bound activity persists for days.
Protein binding	Technetium-99m pertechnetate: <5% bound to plasma proteins. Polyphosphate component: 10-20% bound to albumin and globulins.
Volume of Distribution	Technetium-99m pertechnetate: approximately 0.3 L/kg, reflecting distribution in extracellular fluid. Polyphosphate: higher Vd due to bone uptake.
Bioavailability	Not applicable for IV administration. Oral bioavailability: <1% (not administered orally due to poor absorption and gastric degradation).
Onset of Action	Intravenous: Within minutes (bone uptake begins). Imaging optimal at 2-4 hours post-injection.
Duration of Action	Sufficient for bone scan within 4-6 hours post-injection; imaging window up to 24 hours due to prolonged bone retention.

Classification & Brands

Dosing & administration

Administer intravenously as a single dose of 5-10 mCi (185-370 MBq) of technetium-99m pertechnetate combined with the kit contents, after reconstitution and labeling per manufacturer instructions.

Dosage form	INJECTABLE
Renal impairment	No specific dose adjustment recommended; however, caution is advised in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to potential reduced clearance of the radiopharmaceutical, and imaging may be affected.
Liver impairment	No specific Child-Pugh based adjustments; use caution in severe hepatic impairment as hepatic clearance may be altered, potentially affecting image quality and distribution.
Pediatric use	Weight-based dosing: 0.05-0.1 mCi/kg (1.85-3.7 MBq/kg) with a minimum dose of 1 mCi (37 MBq) and maximum adult dose; adjust based on clinical indication and institutional protocol.
Geriatric use	Elderly patients may require lower dosages due to reduced organ function; consider starting at the lower end of the dose range (5 mCi) and monitor for tolerability; no specific age-based adjustment mandated.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SODIUM POLYPHOSPHATE-TIN KIT (SODIUM POLYPHOSPHATE-TIN KIT).

Breastfeeding	Insufficient data. M/P ratio unknown. Unlikely to be excreted into breast milk in significant amounts due to high molecular weight and rapid clearance. Use caution; consider delaying breastfeeding for 24 hours after administration.
Teratogenic Risk	No adequate human studies. In animal studies, no teratogenic effects observed at clinically relevant doses. First trimester: theoretical risk of fetal hypoxia from maternal cardiovascular effects. Second and third trimesters: potential for fetal bradycardia or hypothyroidism if maternal thyroid function altered (unlikely with diagnostic use).

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to sodium polyphosphate or tin compounds"]

Clinical Precautions

Precautions

["Hypersensitivity reactions including anaphylaxis may occur","Use with caution in patients with impaired liver or spleen function","Pregnancy and lactation: risk-benefit assessment required","Radiopharmaceuticals should be used only by authorized personnel"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

SODIUM POLYPHOSPHATE-TIN KIT

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SODIUM POLYPHOSPHATE-TIN KIT (SODIUM POLYPHOSPHATE-TIN KIT).

How it works

What the body does with it

Metabolism	Not metabolized; the colloid is sequestered by phagocytic cells in the liver, spleen, and bone marrow, and the radionuclide decays physically.
Excretion	Renal elimination of technetium-99m pertechnetate and polyphosphate. Approximately 30% excreted in urine within 24 hours; remainder cleared via bone uptake and slow release. Fecal excretion negligible.
Half-life	Terminal half-life of technetium-99m pertechnetate: 6 hours (physical decay). Biological half-life of polyphosphate variable; bone-bound activity persists for days.
Protein binding	Technetium-99m pertechnetate: <5% bound to plasma proteins. Polyphosphate component: 10-20% bound to albumin and globulins.
Volume of Distribution	Technetium-99m pertechnetate: approximately 0.3 L/kg, reflecting distribution in extracellular fluid. Polyphosphate: higher Vd due to bone uptake.
Bioavailability	Not applicable for IV administration. Oral bioavailability: <1% (not administered orally due to poor absorption and gastric degradation).
Onset of Action	Intravenous: Within minutes (bone uptake begins). Imaging optimal at 2-4 hours post-injection.
Duration of Action	Sufficient for bone scan within 4-6 hours post-injection; imaging window up to 24 hours due to prolonged bone retention.

Classification & Brands

Dosing & administration

Administer intravenously as a single dose of 5-10 mCi (185-370 MBq) of technetium-99m pertechnetate combined with the kit contents, after reconstitution and labeling per manufacturer instructions.

Dosage form	INJECTABLE
Renal impairment	No specific dose adjustment recommended; however, caution is advised in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to potential reduced clearance of the radiopharmaceutical, and imaging may be affected.
Liver impairment	No specific Child-Pugh based adjustments; use caution in severe hepatic impairment as hepatic clearance may be altered, potentially affecting image quality and distribution.
Pediatric use	Weight-based dosing: 0.05-0.1 mCi/kg (1.85-3.7 MBq/kg) with a minimum dose of 1 mCi (37 MBq) and maximum adult dose; adjust based on clinical indication and institutional protocol.
Geriatric use	Elderly patients may require lower dosages due to reduced organ function; consider starting at the lower end of the dose range (5 mCi) and monitor for tolerability; no specific age-based adjustment mandated.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SODIUM POLYPHOSPHATE-TIN KIT (SODIUM POLYPHOSPHATE-TIN KIT).

Breastfeeding	Insufficient data. M/P ratio unknown. Unlikely to be excreted into breast milk in significant amounts due to high molecular weight and rapid clearance. Use caution; consider delaying breastfeeding for 24 hours after administration.
Teratogenic Risk	No adequate human studies. In animal studies, no teratogenic effects observed at clinically relevant doses. First trimester: theoretical risk of fetal hypoxia from maternal cardiovascular effects. Second and third trimesters: potential for fetal bradycardia or hypothyroidism if maternal thyroid function altered (unlikely with diagnostic use).

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to sodium polyphosphate or tin compounds"]

Clinical Precautions

Precautions

Clinical Tips & Counseling

Drug interactions

Loading safety data…